Back to Insights and Updates for ProvidersApril 2023

Opioid Policy Update

Tufts Health Together

While Tufts Health Together will be adopting MassHealth’s Unified Formulary on April 1 for Tufts Health Together, we will follow different thresholds for opioid dosage.

Tufts Health Together will be implementing a number of opioid clinical programs as part of the Unified Formulary. Please refer to the table below for these initiatives, their descriptions, and the implementation date. For more information, including authorization criteria, please refer to Opioids and Analgesics Medical Necessity Guideline.

Initiative  Description Implementation  Date
Quantity Limits Quantity limits restrict opioid dosage forms to 90 morphine milligram equivalent (MME)/day or per the dosing listed in the FDA-approved package labeling. 4/1/2023
120 MME Limit for Single- and Multi-Agent Opioid Regimens Prior authorization will be required if a member’s opioid regimen exceeds 120 MME/day. This limit applies regardless of whether the member’s pain regimen consists of one or multiple opioids. 4/1/2023
High Dose Short-Acting Monotherapy Prior authorization required for short-acting and combination agents when dosage limits are exceeded and the short-acting agents are being used as monotherapy (i.e., no claim for a long-acting opioid agent within the last 30 days). 6/1/2023
Duplicate Long-Acting Opioids For any combination of long-acting opioids, if there is greater than two months of duplicate claims in a member’s claims history, the opioid will require prior authorization. 6/1/2023
Duplicate Short-Acting Opioids For any combination of short-acting opioids, powders, and combination products, if there is greater than two months of duplicate claims in a member’s claims history, then the opioid will require prior authorization. 6/1/2023
Concurrent Therapy with Opioid Dependence Agents Prior authorization is required if a member is stable on any buprenorphine product used for substance use disorder and is attempting to fill a long-acting opioid (for any length of time), a short-acting opioid for more than a 7-day supply, or short-acting opioid(s) for more than 7 days of therapy with the last 30 days.

“Stability” is defined as the following:

  • Buprenorphine/naloxone film or tablet, Zubsolv, or Bunavail: 60 days of therapy within the last 90 days
  • Probuphine (buprenorphine implant): history in the past 210 days
    Sublocade: equal to or greater than 56 days of therapy in the last 84 days

Audrey Kleinberg
Director, Provider Relations & Communications

Annmarie Dadoly
Senior Manager, Provider Communications

Joseph O’Riordan, Jesse Salvato, Stephen Wong

Kristin Edmonston
Production Coordinator

Kristina Cicelova
Graphic Designer